SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.07-0.1%Nov 17 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: B.REVERE who wrote (3947)7/6/1998 11:26:00 AM
From: Frostman  Read Replies (1) of 9523
 
this from WSJ interactive:<<Pfizer Completes Phase I Trial Of Corvas Intl Stroke Therapy
Dow Jones Newswires

SAN DIEGO -- Pfizer Inc. (PFE) completed a Phase I clinical trial of an anti-inflammatory candidate for treating ischemic stroke that was discovered by Corvas International Inc. (CVAS).

When the study began in February, Corvas received a $1-million milestone payment from Pfizer, which has exclusive rights to develop and make the therapeutic agent.

In a press release Monday, Corvas said up to $24 million in potential milestone payments remain in the program. The biopharmaceutical company is also eligible to receive royalty payments on future sales of related products.

The candidate, neutrophil inhibitory factor, has been shown to reduce collateral brain injury following a stroke in animal models.>> EOM
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext